Tag Archive for: Jacobsohn

The future of sickle cell disease treatment through gene therapy

Clumps of sickle cell blocking a blood vessel

In a new review article published in The CRISPR Journal, researchers from Children’s National Hospital discuss the progress of gene therapies for sickle cell disease – from preclinical studies to clinical trials and FDA approval – along with the many challenges of these treatments.

Over the past few years, the advances of gene therapy for sickle cell disease (SCD) offer a potential cure for a condition previously managed only through symptom relief and limited treatments. SCD is a hereditary blood disorder caused by a mutation in the beta globin gene leading to painful symptoms and complications.

In a new review article published in The CRISPR Journal, researchers from Children’s National Hospital discuss the progress of gene therapies for SCD – from preclinical studies to clinical trials and FDA approval – along with the many challenges of these treatments.

“We are hoping to bring attention to the past, present and future of this topic,” says Henna Butt, MD, pediatric hematology oncology fellow at Children’s National and one of the review authors. “It is exciting to see the technology move forward and see how far we have come in a disease where so little progress has been made historically.”

The hold up in the field

Gene therapy for SCD remains a time- and resource-intensive process, often taking several months from the initial patient consultation to treatment.

“Progress in SCD gene therapy has been slowed by high costs, limited accessibility and safety concerns, such as off-target effects,” says Dr. Butt. “Additionally, long-term efficacy data is still needed to confirm the durability of these treatments. Regulatory hurdles and ethical considerations also contribute to the delays.”

Moving the field forward

“By using cutting-edge techniques like CRISPR and base editing to directly correct the genetic mutation responsible for SCD, these therapies have the potential to offer long-term or even permanent relief,” says Dr. Butt. “Success in this area could revolutionize treatment options, improve patient outcomes and reduce the global burden of SCD — especially as therapies become more accessible and affordable.”

“Advancing gene therapy for sickle cell disease requires not just scientific innovation, but also the clinical expertise and systems to deliver it safely and effectively,” says David Jacobsohn, MD, SCM, MBAD, chief of Bone and Marrow Transplantation at Children’s National. “As access expands, we must ensure these therapies reach the patients who need them most.”

The patient benefit

Gene therapy offers a potential cure for SCD, reducing the need for ongoing treatments and significantly improving quality of life. It can lower the risk of complications and infections, and over time, reduce healthcare costs – especially for patients with limited access to traditional care. Raising awareness of current challenges can help drive advocacy for affordability and access.

Children’s National leads the way

Children’s National was the first hospital in the world to collect stem cells for the LYFGENIA™ treatment and one of the few pediatric hospitals in the country that offers both FDA-approved sickle cell disease gene therapies – CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel).

Additional authors from Children’s National include: Mamatha Mandava, MD, and David Jacobsohn, MD, SCM, MBA

Read the full review published in The CRISPR Journal.

Children’s National experts at the 2025 Tandem Meetings

Experts from Children’s National Hospital at the 2025 Tandem Meetings

Nurse Practitioner Sameeya Ahmed-Winston, CPNP, CPHON, was recognized with the APP Lifetime Achievement Award.

Experts from Children’s National Hospital presented and showcased their latest research at the 2025 Tandem Meetings in Hawaii.

This leading global conference on hematopoietic cell transplantation (HCT), cellular therapy and gene therapy brings together top specialists to share groundbreaking discoveries, innovative technologies and the latest scientific advancements shaping the field.

Fellow Henna Butt, MD, won Best Abstract for her research paper – Comparative Analysis of CRISPR-Cas9, Lentiviral Transduction and Base Editing for Sickle Cell Disease Therapy in a Murine Model.

Nurse Practitioner Sameeya Ahmed-Winston, CPNP, CPHON, was recognized with the APP Lifetime Achievement Award.

Additional presenters:

These achievements highlight Children’s National Hospital’s commitment to advancing research and improving treatments for patients with complex conditions. By sharing their expertise on a global stage, these specialists help shape the future of patient care and improve outcomes for children worldwide

Read more highlights from the 2025 Tandem Meetings here.

How our BMT program is excelling: Q&A with David Jacobsohn, M.D.

David Jacobsohn

Dr. Jacobsohn has led the BMT program at Children’s National as the division chief and talks about their incredible success over the last 5 years.

Over the last five years, the bone marrow transplant (BMT) program at Children’s National Hospital has continuously improved. From decreasing transplant-related mortality to 0%, to increasing the complexity of their transplants, the program continues to succeed in providing the best care to patients and their families.

David Jacobsohn, M.D., Blood and Marrow Transplantation division chief, offers insight on the goals the program has reached, the obstacles it has overcome and the vision for what’s next.

Q: How would you describe the success of the BMT program over the last 5 years?

A: We have progressively seen outcomes improve, marked by improvement in one-year overall survival of allogeneic transplants. Contributing to that is our outstanding day 100 transplant-related mortality (TRM). For the first time ever, the day 100 transplant-related mortality, averaged over allogeneic transplants done in the last 3 years, was 0%. That means that during that time, we have not lost a patient due to transplant complications in the first 100 days. This is a remarkable achievement in the world of transplantation.

Q: How does this work move the field forward?

A: We are particularly interested in continuing BMT in non-malignant conditions, such as beta-thalassemia, immunodeficiency and sickle cell anemia. We have one of the largest programs in the country for transplantation of patients with sickle cell anemia. We have been able to offer BMT to patients with sickle cell disease (SCD) and no prior complications, as a preventative procedure. Whereas in the past, it was mostly reserved for patients that had already been severely affected.

Q: How will this work benefit patients?

A: One of the key benefits that we’re seeing is that complications such as graft-versus-host disease (GVHD) have really decreased over the last few years based on the type of medications we’re using and procedures we’re doing.  Now most of our patients that are about six months out from transplant are off immunosuppression and are living relatively normal lives.

Q: What excites you most about this advancement?

A: We’re very excited about something called the Alpha/beta T cell depletion (A/B TCD) . We’re one of the few hospitals in the country offering this process.

This means we’re able to collect the donor stem cells and remove the T cells in the lab. Particularly the A/B T cells, which cause GVHD. We’re able to do this successfully not needing any medications to suppress the immune system. This is really quite novel. A lot of those medications have different side effects on organs, especially the kidneys. Now we can do transplants, even from half-matched donors, without immunosuppression.

We want to expand to more and more patients in the next three to five years so that no patients will need immunosuppression.

Q: What do you look forward to in the next couple of years?

A: In the next few years, we’re excited to venture more into cellular and gene therapy. With regards to cellular therapy, we’re offering something called CAR T cells to patients with acute leukemia. And it’s possible that this will actually replace transplant in some very high-risk leukemia patients.

We’re also looking forward to offering gene therapy to patient with SCD and beta-thalassemia.

Leading blood disorder experts from Children’s National convene in Atlanta for 59th American Society of Hematology annual meeting

In early December 2017, more than 25,000 attendees from around the world, including several experts from Children’s National Health System, convened in Atlanta for the American Society of Hematology’s annual meeting and exposition, the world’s premiere hematology event. For four days, physicians, nurses and other healthcare professionals attended sessions, listened to speakers and collaborated with each other, focusing on enhancing care and treatment options for patients with blood disorders and complications, including leukemia, sickle cell disease and transplants.

As nationally recognized leaders in the field, the Children’s National team led educational sessions and gave keynote speeches highlighting groundbreaking work underway at the hospital, which sparked engaging and productive conversations among attendees. Highlights from the team include:

  • Catherine Bollard, M.D., M.B.Ch.B., Director of the Center for Cancer and Immunology Research, educating global experts on cellular immunotherapy for non-Hodgkin lymphoma.
  • Kirsten Williams, M.D., bone and marrow transplant specialist, presenting novel work utilizing TAA-specific T cells for hematologic malignancies with Dr. Bollard, the sponsor of this first-in-man immunotherapy; moderating sessions on immunotherapy and late complications and survivorship after hematopoietic stem cell transplantation (HSCT).
  • Allistair Abraham, M.D., blood and marrow transplantation specialist, moderating a session on hemoglobinopathies.
  • David Jacobsohn, M.D., ScM, Division Chief of Blood and Marrow Transplantation, moderating a session on allogeneic transplantation results.
  • Naomi Luban, M.D., hematologist and laboratory medicine specialist, introducing a plenary speaker on the application of CRISPR/Cas 9 technology for development of diagnostic reagents for diagnosis of alloimmunization from stem cells.

Additional presentations from the Children’s National team included an oral abstract on the hospital’s work to improve hydroxyurea treatment for sickle cell disease by pediatric resident Sarah Kappa, M.D., who also received an ASH Abstract Achievement Award; another key session on hemoglobinopathies moderated by Andrew Campbell, M.D., director of the Comprehensive Sickle Cell Disease Program; an abstract on the clinical use of CMV- specific T-cells derived from CMV-native donors, presented by Patrick Hanley, Ph.D.; a leukemia study presented by Anne Angiolillo, M.D., oncologist; and a presentation about pain measurement tools in sickle cell disease by Deepika Darbari, M.D., hematologist.

Combined FACT accreditation related to cellular immunotherapy spotlights Children’s ongoing commitment to revolutionary cancer therapies

DNA strand and Cancer Cell

As new immunotherapy treatments are starting to hit the market, care-delivery must adapt so that facilities are prepared to deliver these novel treatments to patients. Children’s National is proud to announce that it became the first pediatric medical institution in the United States to receive accreditations for both immune effector cells and more than minimal manipulation from the Foundation for the Accreditation of Cellular Therapy (FACT). Considered the threshold for excellence in cellular therapy, FACT establishes standards for high-quality medical and laboratory practice in the field.

“We are proud to receive these critically important seals of approval,” said David Jacobsohn, M.D., ScM, division chief of the Division of Blood and Marrow Transplantation at Children’s National. “Our patients are our highest priority and having these accreditations only further demonstrates our commitment to providing the most innovative care.”

The first new designation, FACT Accreditation for Immune Effector Cells, certifies that Children’s National is able to safely administer cutting-edge cellular therapies and monitor and report patient outcomes. The designation applies to CAR-T cells and therapeutic vaccines, among other therapies.

“We continuously set high standards for cellular therapy within the walls of Children’s National, and we are thrilled to be recognized for our leadership in this field,” said Catherine Bollard, M.D., M.B.Ch.B., director of the Center for Cancer and Immunology Research within the Children’s Research Institute. “Cell therapies represent the next generation of cancer treatment, and we are excited to continue our journey in revolutionizing patient care.”

Children’s National also received FACT Accreditation for More than Minimal Manipulation,

a designation that is unique to only a few pediatric institutions in the United States. This accreditation certifies that Children’s National is prepared to safely manufacture its own cellular therapies.

“Being accredited for More than Minimal Manipulation is a tremendous achievement for us as a stand-alone pediatric institution; it exemplifies our ability to manufacture our own innovative cellular therapy products for patients in need,” said Patrick Hanley, Ph.D., director of the Cellular Therapy Laboratory where the cells are manufactured for clinical use. “These two accreditations allow Children’s National to serve as a complex immunotherapy center that is capable of providing immunotherapies and gene therapies from external groups and companies.”

Training t-cells, essential players in the immune system, to fight a trio of viruses

Children's is the only U.S. pediatric hospital that manufactures specialized T-cells from native cord blood

What’s Known
Following treatment, patients with leukemia, lymphoma, and other cancers may receive a transplant in order to restore their body’s natural ability to fight infection and, sometimes, such transplants are a component of leukemia treatment. (Leukemia is the second most common blood cancer, after lymphoma, and its incidence rate has increased by 0.2 percent annually from 2002 to 2011.) A stem cell or cord blood transplant restores the body’s ability to produce infection-fighting white blood cells. After such transplants, however, patients can face heightened risk of developing a life-threatening infection with such viruses as adenovirus, cytomegalovirus, or Epstein-Barr virus.

What’s New
A head-to-head comparison of two strategies to thwart such viral infections shows that both approaches leverage the power of multivirus-specific, donor-derived T-cells (mCTL), which are highly skilled at recognizing foreign invaders. The research team, made up of nine scientists and clinicians affiliated with Children’s National Health System, grew personalized T-cells from peripheral blood (PB) of adult donors who were seropositive for CMV and also coaxed T-cells to grow from naïve cord blood (CB). PB-derived cells have long memories of past battles; naïve CB-derived cells need additional training to acquire such skills. From 35 to 384 days after their stem cell or cord blood transplant, 13 patients were infused with PB mCTL and 12 patients were infused with CB mCTL. Within four weeks, patients experienced up to a 160-fold increase in virus-specific T-cells, which coincided with their response to therapy. Overall response rate was 81 percent.

Questions for Future Research
Q: Could T-cells be personalized to attack other viruses that infect patients post-transplant, such as human parainfluenza virus and BK polyomavirus, providing the potential to target five viruses in a single infusion?
Q: Could the proteins that are used to train T-cells to attack certain viruses also be used to create a personalized approach to tumor suppression?

Source: “A Phase 1 Perspective: Multivirus-Specific T Cells From Both Cord Blood and Bone Marrow Transplant Donors.” Hanley, P., M. D. Keller, M. Martin Manso, C. Martinez, K. Leung, C.R. Cruz, C. Barese, S. McCormack, M. Luo, R.A. Krance, D. Jacobsohn, C. Rooney, H. Heslop, E.J. Shpall, and C. Bollard. Presented during the International Society for Cellular Therapy 2016 Annual Meeting, Singapore. May 26, 2016.